Johnson & Johnson (JNJ)

132.40
1.00 0.79
NYSE : Health Technology
Prev Close 131.36
Open 132.50
Day Low/High 131.96 / 132.50
52 Wk Low/High 121.00 / 148.99
Volume 446.84K
Avg Volume 7.24M
Exchange NYSE
Shares Outstanding 2.64B
Market Cap 344.52B
EPS 5.70
P/E Ratio 21.65
Div & Yield 3.80 (2.80%)

Latest News

Charts of Alcon Look Good

Charts of Alcon Look Good

Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.

Boom or Bust?: Cramer's 'Mad Money' Recap (Thursday 8/15/19)

Boom or Bust?: Cramer's 'Mad Money' Recap (Thursday 8/15/19)

It's not really a boom or a bust, says Jim Cramer. The truth is we're muddling along. But it's hard to outrun the bond bears.

Scanning for Opportunities Thursday

You need to let shares settle down first before nibbling and that will require some time.

Post Call Follow-Up With Stock Ideas on Wednesday's Decline

We want to reiterate some of the buy levels we discussed on the call.

Last Week's Portfolio Updates

Here's our recap.

Stuck in a Rut

The Russell 2000, the Transports and the Bank Index haven’t gone anywhere for around nine months -- until this changes for the better, it’s unlikely the bulls can expect any sort of runaway train on the upside.

Weekly Roundup

We are staying the course, using bouts of panic to buy up the stocks of high-quality companies on discounts.

Adding to Johnson & Johnson

With Treasury yields continuing to fall, we believe JNJ represents a strong name in which to put funds to work.

Adding to a Healthcare Name

Our plan on big down days like this is to make small, incremental buys at each day-stage of the market.

Another Check on Every Portfolio Name: Where Would We Buy?

We are taking a moment to provide price levels for nearly every position in the portfolio.

Johnson & Johnson says Jury Rules in its Favor in Cancer Case

Johnson & Johnson says Jury Rules in its Favor in Cancer Case

Johnson & Johnson said a Kentucky jury rejected claims that its baby powder contained asbestos and caused mesothelioma.

Weekly Roundup

While the trade war is clearly intensifying, we are viewing the market through a buyers' lens, waiting for pullbacks that improve our basis.

Video: Jim's Daily Rundown for Wednesday

Jim breaks down the Apple quarter, shares his thoughts on Lam Research and Twilio ahead of tonight's earnings, and much more!

Weekly Roundup

Markets see solid performance during busy earnings season week.

Checking in on Every Portfolio Name: Where Would We Buy?

We are providing buy price levels for nearly every position in the AAP portfolio.

Weekly Roundup

Markets pull back as earnings season gets underway.

Go for the Easy Money: Cramer's 'Mad Money' Recap (Thursday 7/18/19)

Go for the Easy Money: Cramer's 'Mad Money' Recap (Thursday 7/18/19)

Jim Cramer says Netflix just went from being an easy-money stock to a hard-money stock. Investors need to know the difference.

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.

Small Caps Rise as Traders Change Channel on NFLX, Other Big Caps

Small Caps Rise as Traders Change Channel on NFLX, Other Big Caps

It's a stock picker's market as action in individual stocks is better than on the indexes.

Complacent Market Players Keep It Chill -- as Sparks Fly All 'Round

Complacent Market Players Keep It Chill -- as Sparks Fly All 'Round

It is still a surprisingly sedate market, despite indexes sitting close to all-time highs, earnings season, possible interest-rate cuts and endless speculation about China trade.

Dow Ends Lower; Stocks Slip as Trump Fans China Trade Worries

Dow Ends Lower; Stocks Slip as Trump Fans China Trade Worries

The Dow ends down after reaching an intraday day Tuesday as President Trump says the U.S. and China have `a long way to go' before reaching a trade agreement.

Johnson & Johnson Beats With Second Quarter Results

We think JNJ's valuation is still cheap as it has a below market multiple despite consistent earnings growth.

Video: Jim's Daily Rundown for Tuesday

Jim shares his thoughts on earnings from JPMorgan Chase, Goldman Sachs and Johnson & Johnson.

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is the #18 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, JNJ claims the #263 spot.

TheStreet Quant Rating: B (Buy)